Memantine LEK
País: União Europeia
Língua: búlgaro
Origem: EMA (European Medicines Agency)
Folheto informativo - Bula
(PIL)
16-11-2020
Características técnicas
(SPC)
16-11-2020
Relatório de Avaliação Público
(PAR)
29-04-2013
Ingredientes ativos:
мемантин хидрохлорид
Disponível em:
Pharmathen S.A.
Código ATC:
N06DX01
DCI (Denominação Comum Internacional):
memantine
Grupo terapêutico:
Psychoanaleptics и други анти-деменция лекарства
Área terapêutica:
Болест на Алцхаймер
Indicações terapêuticas:
Лечение на пациенти с умерена до тежка болест на Алцхаймер.
Resumo do produto:
Revision: 5
Status de autorização:
упълномощен
Data de autorização:
2013-04-21
Folheto informativo - Bula
Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on +31 (0)88 781 7600.
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call +31 (0)65 008 9457 outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]
Leia o documento completo
Características técnicas
Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on +31 (0)88 781 7600.
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call +31 (0)65 008 9457 outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]
Leia o documento completo
